X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Mary Dibiase Sells 22,258 Shares

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Mary Dibiase sold 22,258 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $10,016.10. Following the transaction, the chief operating officer now owns 490,980 shares in the company, valued at $220,941. This represents a 4.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

X4 Pharmaceuticals Trading Up 3.0 %

NASDAQ XFOR opened at $0.49 on Tuesday. The stock’s fifty day moving average price is $0.55 and its 200-day moving average price is $0.61. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The stock has a market cap of $83.84 million, a P/E ratio of -5.46 and a beta of 0.14. X4 Pharmaceuticals, Inc. has a 12 month low of $0.26 and a 12 month high of $1.60.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Stifel Nicolaus reduced their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a report on Tuesday, January 14th.

Institutional Trading of X4 Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp increased its position in shares of X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after acquiring an additional 189,105 shares in the last quarter. Ensign Peak Advisors Inc boosted its stake in X4 Pharmaceuticals by 4.6% during the 2nd quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after purchasing an additional 111,032 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of X4 Pharmaceuticals by 15.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock worth $418,000 after purchasing an additional 81,968 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of X4 Pharmaceuticals in the third quarter worth $340,000. Finally, AQR Capital Management LLC raised its position in X4 Pharmaceuticals by 1,080.3% in the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after buying an additional 388,115 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.